The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful drug launches ever. The pill's lower cost compared to the Wegovy injection and Lilly's Foundayo tablet contributes to its popularity. This strong demand highlights ongoing interest in effective weight-loss therapies in the US market.
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
Novo Nordisk is rated a strong buy, offering a 4.2% dividend yield and trading at a 40% discount to its fair value. Although growth is currently pressured by U.S. price cuts and competition, the company is expected to achieve double-digit growth from...
Bitcoin dropped to its lowest level since February, falling as much as 2.3% due to record outflows from spot Bitcoin ETFs totaling $2.3 to $2.8 billion and weakening institutional demand. Strategy's sale of 32 bitcoins, its first in nearly four years...
